Novartis is working closely with healthcare professionals during the coronavirus disease pandemic. We are embracing new ways of working and have rapidly scaled up multichannel engagement including:
- COVID-19 educational podcasts
- Disease-specific podcasts and webcasts covering patient management in light of COVID-19
- Virtual meetings with Novartis representatives, Medical Science Liaisons (MSLs) and account managers
- Provision of free Veeva Engage licenses to aid digital engagement
- Increasing use of professional social channels including LinkedIn and Doximity (US)
- Utilization of new digital channels to engage healthcare professions (e.g. WeChat in China)
Healthcare professional support and resources during COVID-19 are generally provided at country-level in local languages through dedicated HCP portals which in most countries require registration or self-certification. Additional public information can be found in the COVID-19 sections of our country websites. The COVID-19 Information Center provides our latest global updates and easy navigation to local information.
Sandoz educational webcasts for HCPs can be found at www.sandozlive.com in English and Spanish languages. The program focuses on knowledge sharing and best practices.
Congresses and events
As medical congresses are postponed, cancelled or moved online because of COVID-19, Novartis is committed to staying connected to the medical and scientific community. Whenever possible Novartis will continue to participate in events through virtual congress booths and other digital engagement channels.
Details of Novartis participation in virtual events will be provided on our global and country websites, including HCP portals, and social media channels. The Medical Congresses and Events center brings together the growing collection of resources around medical congresses and events.
COVID-19 HCP Webinars
The highlights of the Novartis COVID-19 Webinar, held in May, have been brought together under COVID-19 webinar: Bridging Perspectives.
Novartis has enacted mitigation plans where needed to protect the integrity of our clinical trials and help ensure continuity of treatment.
In partnership with the research community, Novartis is assessing whether our clinical-stage investigational and approved medicines could be repurposed beyond their intended or approved indications to treat complications of COVID-19. We are sponsoring and co-sponsoring multiple large clinical trials of our existing medicines as potential COVID-19 treatments.
Novartis is also supporting a number of Investigator-Initiated Trials (IITs) relating to potential COVID-19 treatments.
Side effects of Novartis medicines can be reported online or to local Novartis Drug Safety Responsible at report.novartis.com
Healthcare professionals can contact Novartis through country HCP portals.